3SP6 image
Entry Detail
PDB ID:
3SP6
Keywords:
Title:
Structural basis for iloprost as a dual PPARalpha/delta agonist
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2011-07-01
Release Date:
2011-07-20
Method Details:
Experimental Method:
Resolution:
2.21 Å
R-Value Free:
0.23
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Peroxisome proliferator-activated receptor alpha
Chain IDs:A
Chain Length:285
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Peroxisome proliferator-activated receptor gamma coactivator 1-beta
Chain IDs:B
Chain Length:11
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.
J.Biol.Chem. 286 31473 31479 (2011)
PMID: 21775429 DOI: 10.1074/jbc.M111.266023

Abstact

Iloprost is a prostacyclin analog that has been used to treat many vascular conditions. Peroxisome proliferator-activated receptors (PPARs) are ligand-regulated transcription factors with various important biological effects such as metabolic and cardiovascular physiology. Here, we report the crystal structures of the PPARα ligand-binding domain and PPARδ ligand-binding domain bound to iloprost, thus providing unambiguous evidence for the direct interaction between iloprost and PPARs and a structural basis for the recognition of PPARα/δ by this prostacyclin analog. In addition to conserved contacts for all PPARα ligands, iloprost also initiates several specific interactions with PPARs using its unique structural groups. Structural and functional studies of receptor-ligand interactions reveal strong functional correlations of the iloprost-PPARα/δ interactions as well as the molecular basis of PPAR subtype selectivity toward iloprost ligand. As such, the structural mechanism may provide a more rational template for designing novel compounds targeting PPARs with more favorable pharmacologic impact based on existing iloprost drugs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures